GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.
OBJECTIVES: Glucagon-like peptide 2 (GLP2) is an intestinal growth factor that has been shown to stimulate intestinal growth and reduce disease severity in preclinical models of short bowel syndrome and inflammatory bowel disease. Teduglutide, a recombinant human GLP2 variant (GLP2-2G), has increase...
Main Authors: | Susan E Alters, Bryant McLaughlin, Benjamin Spink, Tigran Lachinyan, Chia-wei Wang, Vladimir Podust, Volker Schellenberger, Willem P C Stemmer |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3506575?pdf=render |
Similar Items
-
GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One. 2012; 7(11): e50630.
by: Susan E Alters, et al.
Published: (2013-01-01) -
Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.
by: Nathan C Geething, et al.
Published: (2010-04-01) -
XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic.
by: Akvile Haeckel, et al.
Published: (2016-01-01) -
Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
by: Yangyang Liu, et al.
Published: (2020-11-01) -
Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
by: Sara Heidarzadeh, et al.
Published: (2013-01-01)